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Despite improvements in medical and surgical treatment, infective endocarditis (IE) 
remains a serious disease that carries considerable mortality and morbidity.1) Prosthetic 
valve endocarditis (PVE) is a serious, life-threatening complication of valve replacement 
accounting for 10–30% of all cases of IE with an incidence of 0.3–1.2% per patient per 
year.2) Unfortunately, the incidence of IE has been reported to be increasing, and is strongly 
associated with increasing number of cardiac procedures with implanted prosthetic 
material,3) so PVE is inevitable upcoming issue in recent era.
Due to treatment advances, the mortality rate of PVE has dramatically decreased over time, 
however, mortality remains still high and the reason is that complications are more frequent 
due to specific pathogenesis, Staphylococcus aureus4) and technical complexity from extensive 
anatomical destruction during removal of previous prosthesis.
In this issue of Korean Circulation Journal, Pyo et al.5) reported comparative surgical outcomes 
of PVE and native infective endocarditis (NVE). They concluded that PVE carried significant 
perioperative risks (the early mortality rates:14.3%), and was an independent risk factor of 
overall mortality. In detail, PVE patients were older, more commonly had aorto-mitral curtain 
involvement with abscess formation, higher incidences of low cardiac output syndrome 
(mechanical support, 12.5%), newly initiated dialysis (19.6%), reoperation for bleeding 
(14.3%) and early permanent pacemaker implantation (12.5%) compared to NVE group. As 
we know very well, these conclusions similarly accord with previous studies about PVE and 
can easily agree with authors' suggestions.
PVE operation consists of three challenging steps, the first is a safe exposure of heart from 
adhesive condition due to previous operation, the second is a complete extraction pf previous 
infected prosthesis including debridement of infected native tissue, and the third is an 
implantation of new prosthesis in healthy tissue after reconstruction of using autologous or 
bovine pericardium if needed. Every step needs more procedural times, which unavoidably 
induce prolonged cardiopulmonary bypass time, in consequence these are strongly related 
with more postoperative morbidities.
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Survival with regard to location of valve implantation for PVE have shown a superiority in 
aortic position from many studies. Hetzer et al.6) suggested that the survival was significantly 
different after aortic valve replacement (AVR) compared to mitral valve replacement (MVR): 
the 30-day, 1- and 5-year survival for the AVR group was 80±4.8%, 73.7±5.3% and 53±7.2% 
compared to 67.2±6.0%, 50.7±6.4% and 36.9±6.7% for the MVR group (p=0.023) from their 
22-year single-center experience.
The causative agents in PVE are also predicting factors for surgical result and they are 
some different according to onset time after initial valve implantation. The most common 
microorganisms causing early PVE (within two months of implantation) are S. aureus 
(36%), coagulase negative staphylococci (CNS) (17%), and fungi. In PVE occurring later, 
the incidence of S. aureus and CNS decreases (18–20%) in favor of the enterococci and 
Streptococcus viridans (10–13%). Of them, patients with PVE caused by S. aureus represent a 
unique subgroup characterized by increased risk of complications and higher mortality7) and 
PVE caused by Candida species is a rare but catastrophic disease with mortality rates reaching 
37–62.5%,8) and Hetzer et al.6) also suggested that S. aureus (18.1%) was the most frequent 
causative micro-organism and it is strong predictor for in-hospital mortality.
In recent transcatheter aortic valve replacement (TAVR) era, TAVR IE is a rising issue and 
its surgical or medical treatment is a key debate in field of PVE IE. Adnan Khan reported a 
systematic review using 11 studies about TAVR IE and the incidence of post IE varied from 
0–14.3% (3.25%). Enterococci were the most common causative organism isolated from 
25.9% of cases followed by S. aureus (16.1%) and CNS species (14.7%). The mean in-hospital 
mortality and mortality at follow-up was 29.5% and 29.9%, and the septic shock occurred in 
10% and 27.7% TAVR IE patients according to 2 studies. The surgical intervention and valve-
in-valve procedure were reported in 11.4% and 6.4% cases, respectively.9) Until now, surgical 
results for TAVR IE are still unclear because almost patients underwent TAVR initially don't 
want to get surgical AVR and they hesitated or refused for surgical therapy although their 
clinical conditions were very poor from infection. So, only a minority of them (10%) have 
undergone treatment with surgical explantation of the infected prosthesis. Unfortunately, 
the precise role and timing of cardiac surgery in TAVR IE is yet to be defined, with a lack of 
clear evidence to help identify which patients should be offered surgical intervention. Some 
reports were published as a small case series for surgery of TAVR IE and all cases were very 
complicated and challenging in terms of technical complexity and patients' clinical status.
P. G. Malvindi retrieved surgical treatment of TAVR IE, focusing on pre- and intraoperative 
characteristics and early outcome. 37 articles provided information on 107 patients. Their 
mean±standard deviation (SD) age was 76±8 years and 72% were male. The mean ± SD time 
interval between the TAVR procedure and reoperation was 10±10 months. Annular abscess 
formation was described in 34% of cases and MV involvement in 31%. All patients underwent 
TAVR prosthesis explantation and surgical AVR. They suggested that surgical explantation 
of infected TAVR prostheses was associated with a high postoperative mortality, although 
these initial experiences included elderly and high-risk patients. Considering the expansion 
of TAVR recommendation for younger and lower-risk patients, surgical treatment of TAVR IE 
may represent the best option for a life-saving complete procedure.10)
Now, PVE becomes a rising issue in recent increased heart valve procedure era and we have 
to understand completely the clinical characteristics of PVE, from this lesson, set the precise 
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guideline for treatment of PVE, especially transcatheter prosthesis infection which can 
induce hazard complications.
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